FDAnews
www.fdanews.com/articles/199986-biocartis-covid-19-rna-diagnostic-gets-ce-mark

Biocartis’ COVID-19 RNA Diagnostic Gets CE Mark

November 12, 2020

Biocartis has earned CE mark certification for its Idylla SARS-CoV-2 reverse transcription polymerase chain reaction (RT-PCR) test.

The fully automated RT-PCR test provides qualitative detection of coronavirus RNA from nasopharyngeal swabs that use the company’s rapid molecular diagnostics system, Idylla.

The test provides results in 90 minutes, using a single cartridge, and takes less than two minutes of hands-on time, the company said.

View today's stories